ERBB2 and breast cancer: The breast cancer molecular subtypes studied here spanned luminal A (n = 36, 26.7%), luminal B (HER2-) (n = 34, 25.2%), luminal B (HER2+) (n = 25, 18.5%), HER2- enriched (n = 15, 11.1%) and triple-negative breast cancer (TNBC) (n = 25, 18.5%) (Table 1).